Rhythm Pharmaceuticals, Inc. (RYTM)
112.28
+7.26
(+6.91%)
USD |
NASDAQ |
Nov 06, 16:00
112.70
+0.42
(+0.37%)
After-Hours: 20:00
Rhythm Pharmaceuticals Research and Development Expense (Quarterly) : 52.43M for Sept. 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 52.43M |
| June 30, 2026 | 43.38M |
| March 31, 2026 | 41.67M |
| December 31, 2025 | 42.03M |
| September 30, 2025 | 45.92M |
| June 30, 2025 | 42.13M |
| March 31, 2025 | 36.80M |
| December 31, 2024 | 41.00M |
| September 30, 2024 | 37.76M |
| June 30, 2024 | 30.02M |
| March 31, 2024 | 128.47M |
| December 31, 2023 | 29.69M |
| September 30, 2023 | 33.34M |
| June 30, 2023 | 33.32M |
| March 31, 2023 | 37.70M |
| December 31, 2022 | 23.32M |
| September 30, 2022 | 20.89M |
| June 30, 2022 | 31.23M |
| March 31, 2022 | 32.29M |
| December 31, 2021 | 31.36M |
| September 30, 2021 | 27.34M |
| June 30, 2021 | 24.90M |
| March 31, 2021 | 19.71M |
| December 31, 2020 | 21.78M |
| September 30, 2020 | 23.00M |
| Date | Value |
|---|---|
| June 30, 2020 | 23.00M |
| March 31, 2020 | 22.50M |
| December 31, 2019 | 24.81M |
| September 30, 2019 | 26.57M |
| June 30, 2019 | 35.31M |
| March 31, 2019 | 22.76M |
| December 31, 2018 | 18.76M |
| September 30, 2018 | 10.70M |
| June 30, 2018 | 8.584M |
| March 31, 2018 | 12.29M |
| December 31, 2017 | 6.653M |
| September 30, 2017 | 5.971M |
| June 30, 2017 | 5.397M |
| March 31, 2017 | 4.873M |
| September 30, 2016 | 5.419M |
| June 30, 2016 | 4.625M |
| March 31, 2016 | 3.919M |
| December 31, 2015 | 3.618M |
| September 30, 2015 | 2.198M |
| December 31, 2014 | 0.619M |
| September 30, 2014 | |
| June 30, 2014 | 2.496M |
| March 31, 2014 | 2.974M |
| June 30, 2013 | 5.303M |
| March 31, 2013 | 3.776M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Alnylam Pharmaceuticals, Inc. | 408.54M |
| BioMarin Pharmaceutical, Inc. | 180.52M |
| Cytokinetics, Inc. | 95.64M |
| Exelixis, Inc. | 209.48M |
| Ionis Pharmaceuticals, Inc. | 216.41M |